Search Results

Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today provided a corporate update. “Since early this year, we have continued to make great strides in advancing our clinical assets, including initiation of a pilot phase 2 for our newest clinical therapeutic, AKST1210,” said Karoly Nikolich, Ph.D., chief executive officer of Alkahest. “Whils

The transaction, which is set to conclude in early 2021, will give Grifols access to Alkahest’s four product candidates.

Michael Byrnes joins Alkahest as Chief Financial Officer

Bruce Morimoto joins Alkahest as Vice President, Drug Development Operations

Grifols to acquire remaining stock of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis, bringing its ownership of Alkahest to 100%; the transaction is expected to close in early 2021

Alkahest, Inc. today announced the appointment of Elizabeth Jeffords as chief commercial and strategy officer.